Acadias ACP-104 does not meet endpoint in Phase IIb Schizophrenia trial « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
June 2008

M T W T F S S

« May Jul »

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

Acadias ACP-104 does not meet endpoint in Phase IIb Schizophrenia trial

Posted on June 16, 2008 by crimsoncanary

Acadia’s ACP-104 did not meet its primary endpoint of antipsychotic efficacy in a Phase IIb Schizophrenia trial

Filed under: gpcr | Tagged: 5-HT2A, 5HT2A, Acadia, ACP-104, ACP104, agonist, Dopamine, Dopamine D2, Dopamine D3, Muscarinic, Muscarinic M1, phase II

« Merck publish series of new Bradykinin B1 antagonists Takeda to appeal EU negative opinion on melatonin agonist ramelteon »

Leave a Reply